Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
51pct
1d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Insulin Price Reduction Act This bill prohibits health insurance plan issuers and pharmacy benefits managers (PBMs) from receiving rebates or discounts for insulin from manufacturers who certify that its current insulin list price has been reduced to an amount no greater than what the list price was for the same insulin on July 1, 2006. This restriction does not apply to discounts provided to insurance plan holders at retail sale or to flat-rate fees for service paid to PBMs. Further, insurance plans are prohibited from applying a deductible to insulin that has received such price certification. A manufacturer may certify insulin prices by submitting to the Department of Health and Human Services data about the list price of any insulin the manufacturer has produced since January 1, 2000, and by setting the current list price for an insulin product at the 2006 rate. To remain certified, a manufacturer may not increase the list price of insulin by more than the annual increase in the medical care consumer price index. A manufacturer may certify the price of an insulin product for which it did not have a list price in 2006 by reducing the list price of such insulin to the weighted average list price in 2006 of specified insulin categories. This bill also applies to Medicare prescription drug benefits. The bill sets the rebate for insulin under Medicaid based on the average manufacturer price of insulin during the last fiscal quarter of 2019, increasing by the medical care consumer price index thereafter.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · second_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
Client expense: $120,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · second_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
Client expense: $120,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · first_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
Client expense: $80,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · second_quarter · Pharmacy
S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4315/H.R. 6666, COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act. A bill that provides $100 billion in targeted COVID-19 testing funds to medically underserved communities. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R. 7062, Affordable Insulin for the COVID-19 Emergency Act. A bill that eliminates copays for insulin in Medicare Part D during the COVID-19 national emergency period. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4709, Promoting Responsible and Effective Virtual Experiences through Novel Technology to Deliver Improved Access and Better Engagement with Tested and Evidence-Based Strategies (PREVENT DIABETES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.8200, Ending Health Disparities during COVID-19 Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.4550, Minority Diabetes Initiative Act (Lobbyists used: Peter Goelz) H.R.133, Consolidated Appropriations Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott)
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2020 · fourth_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6411 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices H.R. 6649 - Lower Drug Costs for Seniors During COVID-19 Act of 2020 -Schakowsky - COVID H.R. 6739- Ensuring Seniors' Access to COVID Treatments Act - Casten - COVID H.R. 7062 - Affordable Insulin for the COVID-19 Emergency Act - Waters - Insulin/COVID H.R. 8190 - Biosimilar Insulin Access Act of 2020 - Grothman - insulin biosimilar S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs S. 3781 - PART Act - Peters - transparency S. 4134 - Increasing Access to Biosimilars Act of 2020 - Cornyn - CMS demonstration project; provider payments for providing biosimilars S. 4199 - Prescription Drug Pricing Reduction Act of 2020 - Grassley - lower drug prices in Medicare and Medicaid/ transparency S. 4439 - Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020 - Smith - COVID-19 drug be affordable and accessible Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; Executive Orders relating to international pricing, Part D rebates, insulin costs, and importation; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19, including vaccines and therapeutics; issues related to health care price transparency; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2020 · fourth_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act H.R. 3630 - No Surprises Act
Client expense: $60,000 · Firm income: Not reported
2020 · fourth_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
Client expense: Not reported · Firm income: $70,000
2020 · fourth_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: $990,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
2020 · fourth_quarter · Pharmacy
S. 4199 Prescription Drugs Pricing Reduction Act S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D S. 2543, Prescription Drug Pricing Reduction Act HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $160,000 · Firm income: Not reported
2020 · fourth_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act; H.R. 133 Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
2020 · fourth_quarter · Health Issues
S.2199/H.R.4906 Insulin Price Reduction Act support, Special Diabetes Program (extension to 2024)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act
Client expense: $70,000 · Firm income: Not reported
2020 · third_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: $330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
2020 · third_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6411 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices H.R. 6649 - Lower Drug Costs for Seniors During COVID-19 Act of 2020 -Schakowsky - COVID H.R. 6739- Ensuring Seniors' Access to COVID Treatments Act - Casten - COVID H.R. 7062 - Affordable Insulin for the COVID-19 Emergency Act - Waters - Insulin/COVID H.R. 8190 - Biosimilar Insulin Access Act of 2020 - Grothman - insulin biosimilar S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs S. 3781 - PART Act - Peters - transparency S. 4134 - Increasing Access to Biosimilars Act of 2020 - Cornyn - CMS demonstration project; provider payments for providing biosimilars S. 4199 - Prescription Drug Pricing Reduction Act of 2020 - Grassley - lower drug prices in Medicare and Medicaid/ transparency S. 4439 - Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020 - Smith - COVID-19 drug be affordable and accessible Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; Executive Orders relating to international pricing, Part D rebates, insulin costs, and importation; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19, including vaccines and therapeutics; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2020 · third_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals.
Client expense: Not reported · Firm income: $70,000
2020 · third_quarter · Health Issues
S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4315/H.R. 6666, COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act. A bill that provides $100 billion in targeted COVID-19 testing funds to medically underserved communities. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R. 7062, Affordable Insulin for the COVID-19 Emergency Act. A bill that eliminates copays for insulin in Medicare Part D during the COVID-19 national emergency period. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4709, Promoting Responsible and Effective Virtual Experiences through Novel Technology to Deliver Improved Access and Better Engagement with Tested and Evidence-Based Strategies (PREVENT DIABETES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.8200, Ending Health Disparities during COVID-19 Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.8406, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S4318, S4317, S4319, S4320, S4321, S4322, S4323, S432, Health, Economic Assistance, Liability Protection and Schools (HEALS) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4775, Delivering Immediate Relief to America's Families, Schools and Small Businesses Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R. 4932/S.S.2741, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) Issues worked on not yet reflected in legislation: The Associations Health Equity Now initiative. The Association supports equitable access to a cure for diabetes through research, high-quality health care, diabetes drugs and management tools, healthy food and strong communities. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott)
2020 · third_quarter · Pharmacy
S. 4199 Prescription Drugs Pricing Reduction Act S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $200,000 · Firm income: Not reported
2020 · third_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act
Client expense: Not reported · Firm income: $60,000
2020 · second_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. Issues related to hospital inpatient blood glucose monitoring.
Client expense: $110,000 · Firm income: Not reported
2020 · second_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6411 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices H.R. 6649 - Lower Drug Costs for Seniors During COVID-19 Act of 2020 -Schakowsky - COVID H.R. 6739- Ensuring Seniors' Access to COVID Treatments Act - Casten - COVID H.R. 7062 - Affordable Insulin for the COVID-19 Emergency Act - Waters - Insulin/COVID S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs S. 3781 - PART Act - Peters - transparency Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2020 · second_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: $650,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
2020 · second_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: Not reported · Firm income: $60,000
2020 · second_quarter · Pharmacy
S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $160,000 · Firm income: Not reported
2020 · second_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) H.R. 6666, COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act. A bill that provides $100 billion in targeted COVID-19 testing funds to medically underserved communities. (Lobbyists used: Elise Tollefson, Peter Goelz) H.R. 7062, Affordable Insulin for the COVID-19 Emergency Act. A bill that eliminates copays for insulin in Medicare Part D during the COVID-19 national emergency period. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
2020 · second_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
2020 · second_quarter · Health Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act H.R. 6800 - The Heroes Act Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: Not reported · Firm income: $60,000
2020 · first_quarter · Pharmacy
H.R. 3 - Lower Drug Costs Now Act of 2019 - Pallone - drug pricing H.R. 4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Cicilline - drug pricing H.R. 4906 - Insulin Price Reduction Act - DeGette - insulin costs H.R. 5444 - Lower Insulin Costs Now Act - Underwood - lowering insulin costs H.R. 5749 - Affordable Insulin for All Act - Crist - insulin costs H.R. 6155 - To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products - Grothman - biological products H.R. 6426 - To require group health plans and health insurance issuers offering group or individual coverage to provide notices relating to prescription drug refills to individuals covered under such plans or coverage who reside in emergency areas during emergency periods - McBath - prescription drug refill notices S. 2543 - Prescription Drug Pricing Reduction Act of 2019 - Grassley - Drug pricing S. 3092 - Expanding Access to Low-Cost Generics Act of 2019 - Smith - 180-day exclusivity period S. 3166 - Prescription Drug Affordability and Access Act - Booker - prescription drug costs Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2020 · first_quarter · Medicare/Medicaid
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
Client expense: Not reported · Firm income: $40,000
2020 · first_quarter · Pharmacy
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to drug importation in general; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act;
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
2020 · first_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: $610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
2020 · first_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues relates to expanding telehealth under Medicare for the purposes of qualifying visits for insulin pumps and continuous glucose monitors. S. 3548, H.R. 748 - CARES Act
Client expense: $190,000 · Firm income: Not reported
2020 · first_quarter · Health Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: Not reported · Firm income: $60,000
2020 · first_quarter · Pharmacy
S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act S. 3052, Grassley, the US, Mexico and Canada Trade Agreement Implementation Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D HR 4378, Continuing Appropriations and Health Extenders Act S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $670,000 · Firm income: Not reported
2019 · fourth_quarter · Health Issues
Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
Client expense: $920,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (Isakson) - regulations re nonprescription drugs that are marketed without an approved new drug application S. 3052, United States-Mexico-Canada Agreement Implementation Act (Grassley) - drug pricing S. 3067, Non-Opioids Prevent Addiction In the Nation Act (Capito) - non-opioid treatments S. 3092, Expanding Access to Low-Cost Generics Act of 2019 (Smith) - exclusivity period H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.R. 4640, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 (DeFazio) - direct negotiation H.R. 4712, Fairness in Orphan Drug Exclusivity Act (Dean) - limitations on exclusive approval of orphan drugs H.R. 4810, Opioid Prescription Verification Act of 2019 (David) - dispensing of controlled substances H.R. 4906, Insulin Price Reduction Act (Diana DeGette) - insulin costs H.R. 5304, PBM Transparency in Prescription Drug Costs Act (Schrader) - PBMs H.R. 5364, End Price Gouging for Insulin Act (Beatty) - annual reference price for insulin products H.R. 5430, United States-Mexico-Canada Agreement Implementation Act (Hoyer) - drug pricing H.R. 5442, Lowest Price for Patients Act (Porter) - pharmacies to disclose any differential between the cost of a prescription drug H.R. 5444, Lower Insulin Costs Now Act (Underwood) - lowering insulin costs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2019 · fourth_quarter · Health Issues
H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2732: Lessening Addiction By Enhancing Labeling Opioids Act of 2019 - Provisions related to labeling of prescription drugs H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4010: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug access programs H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4814: Suspicious Order Identification Act of 2019 - Provisions related to reporting on distribution of controlled substances H.R. 4906: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices - Provisions related to prescription drug pricing H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45)
2019 · fourth_quarter · Medicare/Medicaid
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
Client expense: Not reported · Firm income: $60,000
2019 · fourth_quarter · Pharmacy
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith, Gwen Rathbun, Deema Tarazi) S. 1895, the Lower Health Care Costs Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), a provision that would end surprise medical billing, and provisions lowering prescription drug costs, which ADA supports. (Lobbyists used: Gwen Rathbun, Robert Goldsmith, Meghan Riley, Deema Tarazi) S.2302, The Americas Transportation Infrastructure Act. Support including provisions for transportation alternative programs, which were included in S.1098 and safe routes to school. (Lobbyist used: Deema Tarazi, Meghan Riley) S.2358, The Wise Investment in Children Act of 2019 (WIC Act). Support extending child eligibility to age six or the beginning of kindergarten; extending infant certification periods to two years; and extending postpartum womens eligibility to two years. (Lobbyist used: Deema Tarazi, Meghan Riley) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Improving access to affordable and adequate health care. The ADA supports continued efforts to protect and expand benefits under the Affordable Care Act (ACA), Medicare, Medicaid, and other health plans to ensure access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)
2019 · fourth_quarter · Pharmacy
S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act S. 3052, Grassley, the US, Mexico and Canada Trade Agreement Implementation Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D HR 4378, Continuing Appropriations and Health Extenders Act S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $670,000 · Firm income: Not reported
| Democratic |
| UT |
| Bennie G. Thompson | Democratic | MS |
| Betty McCollum | Democratic | MN |
| Brendan F. Boyle | Democratic | PA |
| Brian Higgins | Democratic | NY |
| Brian K. Fitzpatrick | Republican | PA |
| C. A. Dutch Ruppersberger | Democratic | MD |
| Chellie Pingree | Democratic | ME |
| Colin Z. Allred | Democratic | TX |
| Cynthia Axne | Democratic | IA |
| Danny K. Davis | Democratic | IL |
| Darren Soto | Democratic | FL |
| David E. Price | Democratic | NC |
| David N. Cicilline | Democratic | RI |
| Debbie Dingell | Democratic | MI |
| Debbie Wasserman Schultz | Democratic | FL |
| Donald M. Payne, Jr. | Democratic | NJ |
| Earl Blumenauer | Democratic | OR |
| Ed Perlmutter | Democratic | CO |
| Elaine G. Luria | Democratic | VA |
| Eleanor Holmes Norton | Democratic | DC |
| Elissa Slotkin | Democratic | MI |
| Gerald E. Connolly | Democratic | VA |
| Haley M. Stevens | Democratic | MI |
| Jahana Hayes | Democratic | CT |
| Jesús G. "Chuy" García | Democratic | IL |
| Joaquin Castro | Democratic | TX |
| John B. Larson | Democratic | CT |
| Josh Harder | Democratic | CA |
| José E. Serrano | Democratic | NY |
| Kim Schrier | Democratic | WA |
| Marcy Kaptur | Democratic | OH |
| Max Rose | Democratic | NY |
| Maxine Waters | Democratic | CA |
| Michael F. Q. San Nicolas | Democratic | GU |
| Mike Kelly | Republican | PA |
| Nita M. Lowey | Democratic | NY |
| Nydia M. Velázquez | Democratic | NY |
| Pete Aguilar | Democratic | CA |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sean Patrick Maloney | Democratic | NY |
| Sharice Davids | Democratic | KS |
| Sheila Jackson Lee | Democratic | TX |
| Steve Cohen | Democratic | TN |
| Susan Wild | Democratic | PA |
| Susie Lee | Democratic | NV |
| Sylvia R. Garcia | Democratic | TX |
| Theodore E. Deutch | Democratic | FL |
| Tom Reed | Republican | NY |
| Vicente Gonzalez | Democratic | TX |
| Wm. Lacy Clay | Democratic | MO |
Client expense: $2,400,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Council of Economic Advisers (CEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $2,230,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, White House Office
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $120,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Client expense: $120,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Client expense: $3,630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $2,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Client expense: $6,450,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE